

Supplementary Materials




Figure S1. TEM images at low magnification to inspect the morphology of (a) blank G4-FITC PAMAM dendrimers; (b) erlotinib conjugated G4-FITC PAMAM dendrimers; (c) blank G5-FITC PAMAM dendrimers; and (d) erlotinib conjugated G5-FITC PAMAM dendrimers.




Figure S2. Particle size distribution by intensity for (a) blank G4-FITC PAMAM dendrimers; (b) erlotinib conjugated G4-FITC PAMAM dendrimers; (c) blank G5-FITC PAMAM dendrimers; and (d) erlotinib conjugated G5-FITC PAMAM dendrimers.




Figure S3. Zeta potential measurements for (a) blank G4-FITC PAMAM dendrimers; (b) erlotinib conjugated G4-FITC PAMAM dendrimers; (c) blank G5-FITC PAMAM dendrimers; and (d) erlotinib conjugated G5-FITC PAMAM dendrimers at pH 5.4.




Figure S4. Zeta potential measurements for (a) blank G4-FITC PAMAM dendrimers; (b) erlotinib conjugated G4-FITC PAMAM dendrimers; (c) blank G5-FITC PAMAM dendrimers; and (d) erlotinib conjugated G5-FITC PAMAM dendrimers at pH 7.4.




Figure S5. HPLC-PDA purity of polyamidoamine (PAMAM) dendrimers G4 and PAMAM dendrimers G5.